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ABSTRACT
OBJECTIVE
To examine whether the continuous updating of 
networks of prospectively planned randomised 
controlled trials (RCTs) (“living” network meta-
analysis) provides strong evidence against the 
null hypothesis in comparative effectiveness of 
medical interventions earlier than the updating of 
conventional, pairwise meta-analysis.
DESIGN
Empirical study of the accumulating evidence about 
the comparative effectiveness of clinical interventions.
DATA SOURCES
Database of network meta-analyses of RCTs identified 
through searches of Medline, Embase, and the 
Cochrane Database of Systematic Reviews until 14 
April 2015.
ELIGIBILITY CRITERIA FOR STUDY SELECTION
Network meta-analyses published after January 2012 
that compared at least five treatments and included at 
least 20 RCTs. Clinical experts were asked to identify 
in each network the treatment comparison of greatest 
clinical interest. Comparisons were excluded for which 
direct and indirect evidence disagreed, based on side, 
or node, splitting test (P<0.10).
OUTCOMES AND ANALYSIS
Cumulative pairwise and network meta-analyses 
were performed for each selected comparison. 
Monitoring boundaries of statistical significance 
were constructed and the evidence against the null 
hypothesis was considered to be strong when the 
monitoring boundaries were crossed. A significance 
level was defined as α=5%, power of 90% (β=10%), 
and an anticipated treatment effect to detect equal to 
the final estimate from the network meta-analysis. The 
frequency and time to strong evidence was compared 
against the null hypothesis between pairwise and 
network meta-analyses.
RESULTS
49 comparisons of interest from 44 networks were 
included; most (n=39, 80%) were between active 
drugs, mainly from the specialties of cardiology, 
endocrinology, psychiatry, and rheumatology. 29 
comparisons were informed by both direct and 
indirect evidence (59%), 13 by indirect evidence 
(27%), and 7 by direct evidence (14%). Both network 
and pairwise meta-analysis provided strong evidence 
against the null hypothesis for seven comparisons, 
but for an additional 10 comparisons only network 
meta-analysis provided strong evidence against 
the null hypothesis (P=0.002). The median time to 
strong evidence against the null hypothesis was 
19 years with living network meta-analysis and 23 
years with living pairwise meta-analysis (hazard ratio 
2.78, 95% confidence interval 1.00 to 7.72, P=0.05). 
Studies directly comparing the treatments of interest 
continued to be published for eight comparisons after 
strong evidence had become evident in network  
meta-analysis.
CONCLUSIONS
In comparative effectiveness research, prospectively 
planned living network meta-analyses produced 
strong evidence against the null hypothesis more 
often and earlier than conventional, pairwise  
meta-analyses.
Introduction
A timelier introduction of effective medical 
interventions was one of the early promises of meta-
analysis of randomised control trials (RCTs).1  2 
Cumulative meta-analysis, defined as updating a 
meta-analysis whenever a new eligible RCT becomes 
available, has been used retrospectively to examine 
how evidence on a given intervention has accrued over 
time and how quickly it has informed guidelines.3  4 
More recently, the optimal time for updating a 
systematic review has been discussed5-7 and guidelines 
and decision tools developed.8-10 In 2014 “living 
systematic reviews” were proposed as a framework for 
continuously updated meta-analyses.11
In recent years, network meta-analyses have gained 
prominence in comparative effectiveness research.12 13 
They extend conventional, pairwise meta-analysis 
to compare multiple treatments within a network of 
RCTs.14-16 A living version of network meta-analysis 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Network meta-analysis is an extension to conventional meta-analysis, which 
includes both direct and indirect evidence on the comparative effectiveness of 
multiple treatments
Network meta-analysis might produce strong evidence against the null 
hypothesis on the comparative effectiveness of treatments earlier than standard 
pairwise meta-analysis but requires more assumptions and advanced statistical 
methods
Sequential methods for analysis of “living” network meta-analysis of 
prospectively planned randomised controlled trials have recently become 
available, allowing the continuous updating of evidence
WhAT ThIS STudy AddS
Network meta-analysis was 20% more likely to provide strong evidence against 
the null hypothesis of treatment differences than pairwise meta-analysis
Network meta-analysis provided strong evidence against the null hypothesis four 
years earlier than pairwise meta-analysis
Prospectively planned living network meta-analysis can facilitate timely 
recommendations and contribute to reduce research waste by providing strong 
evidence against the null hypothesis earlier than living pairwise meta-analysis
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has recently been suggested as the new paradigm in 
comparative effectiveness research.17 18 Healthcare 
institutions such as the UK National Institute for 
Health and Care Excellence and the World Health 
Organization consider network meta-analyses and, 
if there is high confidence in the results, use them to 
inform recommendations.19 By including both direct 
and indirect evidence, continuously updated network 
meta-analysis can reach robust conclusions on the 
relative effectiveness of treatments earlier than pairwise 
meta-analyses, thus potentially facilitating timely 
recommendations and reducing research waste.17-20
In a prospectively planned network meta-analysis, 
studies are designed and realised using a predefined 
protocol and they are cumulatively synthesised as 
their results become available. One study highlighted 
the potential of this approach to optimally inform 
comparative effectiveness of drugs, not only at the 
post-marketing stage but also before licensing.21 In 
the framework of a prospective living network meta-
analysis, suitable methods are required for statistically 
monitoring the accumulating evidence while 
controlling for the risk of falsely concluding superiority 
of an intervention. Such methods have been developed 
recently, extending the sequential monitoring of trials 
and pairwise meta-analyses.18 22 It is, however, unclear 
whether the theoretical potential of prospectively 
planned living network meta-analysis can be realised 
in comparative effectiveness research and whether 
its increased power compared with pairwise meta-
analysis is or is not substantial. We used sequential 
monitoring to assess recently published network meta-
analyses of RCTs of medical interventions to examine 
whether living network meta-analysis would have 
provided strong evidence against the null hypothesis 
more often and earlier than the corresponding updated 
pairwise meta-analysis.
Methods
Search strategy and inclusion criteria
We compiled a large database of network meta-analyses 
of RCTs based on searches of Medline, Embase, and 
the Cochrane Database of Systematic Reviews from 
inception to 14 April 2015.12 In the present study 
we included networks published after January 2012, 
as empirical evidence suggested that the quality 
of the systematic reviews and statistical rigor have 
considerably improved in recent years.12 To ensure 
a critical mass of data, we included networks with at 
least one closed loop of evidence that compared at 
least five different treatments and included 20 or more 
RCTs published within at least 10 years.
Selection of comparison of interest
We focused on treatment comparisons that were of 
interest to the developers of clinical guidelines during 
the period the body of evidence accumulated. For 
each included network meta-analysis we asked senior 
clinicians or clinical researchers with experience 
in guideline development to choose the treatment 
comparison that “was of greatest interest to the 
developers of guidelines or which had the greatest 
influence on clinical decision-making during the 
indicated time period” and to justify their choice by 
providing a reference of a relevant clinical guideline. 
One expert evaluated each network and the comparison 
was chosen independently of the availability of direct 
or indirect evidence. Experts were blind to the results 
of the sequential analysis. Treatment effects were 
expressed as the standardised mean difference, odds 
ratios, or hazard ratios for continuous, binary, and 
time-to-event data, respectively.
Network meta-analysis rests on the assumption of 
consistency between direct and indirect evidence. We 
therefore excluded networks where the comparison of 
interest showed evidence of inconsistency, defined by a 
P value less than 0.10 when direct and indirect evidence 
were compared in a z test (Separate Indirect from Direct 
Evidence (SIDE), also called node splitting test).23
Construction of monitoring boundaries and 
definition of strong evidence
We assumed that studies had been prospectively 
planned and that they were included in the synthesis 
model once results became available. Then we 
evaluated the evidence against the null hypothesis 
using hypothesis testing to decide whether further 
data were needed. Repeatedly testing whenever new 
evidence is added to a body of evidence leads to 
inflated type I errors.22-25 Methods originally developed 
for sequential analysis of RCTs have been adapted to 
cumulative pairwise meta-analysis and more recently 
to network meta-analysis.18 26 We used an adaptation 
of α spending functions, which we have described in 
detail elsewhere.18 Firstly, we defined an anticipated 
treatment effect to detect rates of type I and type II 
errors (α and β, respectively). Secondly, we constructed 
the α spending function boundary as a function of the 
statistical information (added at each update) and 
the maximum information. Statistical information 
is defined as the inverse of the variance—that is, 
precision. We defined the maximum information as the 
precision of a single RCT that is adequately powered 
to detect the anticipated difference between the 
two interventions, given α and β. The α error is then 
distributed along the sequential tests, with smaller 
values “spent” for early tests and larger values spent 
at later stages. The monitoring boundaries correspond 
to the quantiles of the α levels and approximate the 
(1−α/2) % quantile of thestandard normal distribution 
as the statistical information approaches its maximum. 
We implemented the methods in a freely available R 
package (see appendix N).
We defined a significance level α=5%, power of 
90% (β=10%) and an anticipated treatment effect to 
detect equal to the final estimate from the network 
meta-analysis. We expressed results as z scores (ie, the 
effect size divided by its standard error). In the primary 
analysis for both pairwise meta-analysis and network 
meta-analysis, we imputed the median value of the 
empirical distributions from Cochrane reviews.27 28 
In a sensitivity analysis, we estimated heterogeneity 
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from the data at each update. We considered that a 
pairwise or network meta-analysis provided strong 
evidence against the null hypothesis (the hypothesis 
that there is no difference between the interventions) 
when the accumulated information crossed the 
monitoring boundaries of statistical significance, 
constructed as described here and previously.18 We 
define strong evidence as strong evidence against the 
null hypothesis.
Example: olanzapine versus haloperidol in 
schizophrenia
We illustrate the approach using the example of the 
relative efficacy of olanzapine and haloperidol in the 
acute treatment of schizophrenia, based on one of 
the network meta-analyses included in this study29 
(fig 1). We assume a standardised mean difference 
measuring the overall change in symptoms of 0.13 
favouring olanzapine, equal to the final estimate 
from the random effects network meta-analysis, and 
type I and type II errors of 5% and 10%, respectively. 
The first RCT to compare olanzapine and haloperidol 
was published in 1996.30 The results showed that 
olanzapine tended to reduce symptoms more than 
haloperidol: the standardised mean difference was 
0.07 and the z score was 0.26.30 Until 2007, a further 
10 RCTs that directly compared the two drugs were 
published, resulting in a summary standardised 
mean difference of 0.12 favouring olanzapine (95% 
confidence interval −0.07 to 0.30); these results are 
added sequentially in cumulative pairwise meta-
analysis (fig 1). In network meta-analysis the z 
score is updated whenever new direct or indirect 
evidence becomes available (fig 1). Indirect evidence 
accumulates through RCTs that compare the drugs of 
interest with placebo or another drug. At any time, 
the accumulated information is compared with the 
monitoring boundaries. The direct evidence from 
cumulative pairwise meta-analysis remains within 
the boundaries, whereas the mixed evidence (direct 
and indirect) from network meta-analysis crosses the 
monitoring boundaries in 2008 (after the inclusion 
of 131 RCTs in the entire network), indicating strong 
evidence against the null hypothesis for the superiority 
of olanzapine (fig 1). The standardised mean difference 
at the point of crossing the stopping boundary was 
0.13 (95% confidence interval 0.02 to 0.24). Appendix 
M shows an alternative presentation of sequential 
monitoring using repeated confidence intervals.
Comparing living network meta-analysis and living 
pairwise meta-analysis
We compared the emergence of strong evidence against 
the null hypothesis (defined as crossing monitoring 
boundaries) between living pairwise and network 
meta-analyses. Among comparisons with strong 
evidence we examined whether boundaries were 
crossed as a result of indirect evidence. We analysed 
data in a 2×2 table using McNemar’s exact test and 
estimated differences in the probability of providing 
strong evidence. We plotted Kaplan-Meier curves and 
calculated the hazard ratio from a frailty time-to-event 
regression model to describe the time needed to cross 
the boundary while accounting for the paired nature 
of the data.31 For comparisons with strong evidence 
against the null hypothesis we recorded how many 
studies that directly compared the treatments were 
published after the boundaries had been crossed. All 
analyses were done in a frequentist framework using 
R (R Development Core Team, Vienna, Austria) and 
Stata (Stata, College Station, TX). Appendices K and N 
include the technical details about the R package, and 
worked examples.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in the design and implementation of the study. 
No patients were asked to advise on interpretation or 
writing up of results. There are no plans to disseminate 
the results of the research to study participants or the 
relevant patient community.
Results
Database of network meta-analyses
Out of 456 published network meta-analyses included 
in the original database,12 44 met the inclusion 
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Fig 1 | Efficacy of olanzapine versus haloperidol in 
treatment of acute schizophrenia, as estimated from 
living pairwise meta-analysis and living network meta-
analysis. Monitoring boundaries were constructed using 
an α spending function with type I and type II errors fixed 
at 5% and 10%, respectively. Conventional significance 
thresholds are shown as dotted lines (z=1.96). The 
horizontal axis shows statistical information that 
accumulated over time, compared with maximum 
statistical information (information in single adequately 
powered study). Heterogeneity variance is assumed to be 
equal to the median of predictive distributions (0.049)
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criteria. The most important reasons for exclusion 
were publication before January 2012 and lack of 
outcome data (see appendix figure 1). The 44 network 
meta-analyses were published in 38 journals (28 
specialist and 10 general medicine journals) (table 1). 
Most networks addressed research questions in the 
specialties of cardiology, endocrinology, psychiatry, 
and rheumatology (table 1). Clinical experts selected 54 
treatment comparisons, and five were excluded owing 
to evidence of inconsistency (table 2, and see appendix 
table 1). Most of the 49 included comparisons were 
between two drug interventions (n=39, 80%). Five 
comparisons (10%) involved placebo, two (4%) were 
between invasive interventions, and four (8%) involved 
lifestyle modifications. Most primary outcomes were 
binary (66%) or continuous (23%) (table 1).
Of the 49 comparisons, 29 (59%) were informed 
by both direct and indirect evidence in the network 
meta-analysis. The P values from testing for agreement 
between indirect and direct evidence ranged between 
0.11 and 0.99 (see appendix table 1). Thirteen 
comparisons (27%) were not examined directly in any 
RCT; seven (14%) were based on direct evidence only.
Comparison of living pairwise and network meta-
analyses
For 10 of the 49 comparisons (20%), the evidence for 
superiority of one of the interventions was stronger 
with network meta-analysis than with pairwise meta-
analysis. In seven instances (14%) both pairwise and 
network meta-analyses provided strong evidence 
against the null hypothesis, whereas in 32 comparisons 
neither analysis produced strong evidence (table 3, 
P=0.002 from McNemar’s exact test). Network meta-
analysis was 20% more likely (95% confidence interval 
10% to 35%) to provide strong evidence against the 
null hypothesis than pairwise meta-analysis. Results 
were similar when heterogeneity was estimated rather 
than imputed (see appendix table 2) or when summary 
effects from pairwise meta-analysis instead of network-
meta-analysis were used to define the anticipated 
treatment effect to detect (see appendix table 3). 
Restricting analyses to comparisons for which both 
direct and indirect evidence were available did not 
materially change results (P=0.016 from McNemar’s 
test, see appendix table 4).
For nine out of the 17 treatment comparisons where 
network meta-analyses provided strong evidence 
against the null hypothesis (53%), this was achieved 
only after adding an RCT that contributed indirect 
evidence. For 13 treatment comparisons there was no 
RCT directly comparing the interventions of interest, 
and yet for three of them strong evidence was available 
by indirect comparison (table 2): exercise and non-
steroidal anti-inflammatory drugs versus exercise for 
pain relief,32 nifedipine versus placebo for delaying 
delivery in women at risk of preterm delivery,33 and 
candesartan versus topiramate for the prevention of 
migraine.34
Median time to strong evidence against the 
null hypothesis (the first time that the monitoring 
boundary was crossed) was 19 years (interquartile 
range 16 to 23) with network meta-analysis and 23 
years (interquartile range not estimable) with pairwise 
meta-analysis (fig 2). Network meta-analysis provided 
strong evidence earlier than pairwise meta-analysis, 
by 4 years (95% confidence interval 0 to 7 years). The 
hazard ratio comparing network with pairwise meta-
analysis was 2.78 (95% confidence interval 1.00 to 
7.72; P=0.05). For eight (47%) of the 17 comparisons 
with strong evidence, studies directly comparing the 
treatments of interest continued to be published after 
the boundary had been crossed (see appendix table 1). 
The total number of additional studies was 66; 40 of 
these compared edaravone with placebo.35 Appendix 
Table 1 | Characteristics of 44 network meta-analyses and 49 network comparisons of 
medical interventions included in study. Values are numbers (percentages) unless stated 
otherwise
Network meta-analyses Estimates
Median (interquartile range): n=44
 No of studies included 41 (26-60)
 No of treatments compared 9 (8-14)
 Span of years 21 (16-34)
 Total sample size 10 587 (3494-26 089)
Outcome characteristics
Direction of effect:
 Beneficial 22 (50)
 Harmful 22 (50)
Outcome type:
 Objective 17 (39)
 Semi-objective* 19 (43)
 Subjective† 8 (18)
Measurement:
 Binary 29 (66)
 Continuous 10 (23)
 Rate 1 (2)
 Time to event 4 (9)
Journal (No of distinct journals):
 General medicine (n=10) 16 (36)
 Specialty (n=28) 28 (64)
Medical specialty:
 Cardiology 9 (20)
 Endocrinology 6 (13)
 Psychiatry 5 (11)
 Rheumatology 5 (11)
 Neurology 3 (7)
 Dentistry/periodontology 3 (7)
 Pulmonology 3 (7)
 Dermatology 2 (5)
 Gastroenterology 2 (5)
 Obstetrics 2 (5)
 Oncology 2 (5)
 Anaesthesiology 1 (2)
 Hepatology 1 (2)
Comparisons: n=49
 Drug versus drug 39 (80)
 Drug versus placebo 4 (8)
 Lifestyle versus drug 2 (4)
 Lifestyle versus lifestyle and placebo 1 (2)
 Lifestyle versus lifestyle and drug 1 (2)
 Invasive versus invasive 2 (4)
*Cause specific mortality, major morbidity event, composite mortality or morbidity, obstetric outcomes, internal 
structure, external structure, surgical device success or failure, withdrawals or drop-outs, resource use, and 
hospital stay or process measures.27
†Pain, mental health outcomes, dichotomous biological markers, quality of life or functioning, consumption, 
satisfaction with care, general physical health, adverse events, infection or new disease, continuation or 
termination of condition being treated, and composite endpoint (including at most one mortality or morbidity 
endpoint).27
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table 5 shows the results from pairwise and network 
meta-analyses for each medical specialty.
In a scatterplot of the precision of estimates 
from pairwise and network meta-analyses, there 
was a clear gain in precision with network meta-
analysis (see appendix figure 2). In almost half of the 
comparisons (13 out of 29 comparisons, 45%) the 
network meta-analysis produced a 95% confidence 
interval the width of which was less than two thirds 
of the interval from pairwise meta-analysis. Appendix 
figure 3 presents the continuous updating (as z 
scores along with monitoring boundaries) of pairwise 
and network meta-analysis for all 49 comparisons 
included in this study.
Table 2 | Treatment comparisons selected in each network, type of evidence (direct, indirect, or both), and meta-analysis method that provides 
strong evidence against similarity of treatments for primary outcome studied (see appendix for more detailed version of table)
Network Comparison of greatest interest
Type of 
 evidence
Design providing strong 
evidence
Network  
meta-analysis Meta-analysis
Buti 2013 Coronally advanced flap and connective tissue graft versus coronally advanced flap and 
enamel matrix derivative
Both No No
Dogliotti 2013 Vitamin K antagonists versus apixaban Both No No
Naci 2013 Atorvastatin versus rosuvastatin Both No No
Filippini 2013 β interferon-1a (Avonex) versus β interferon-1a (Rebif) Both No No
Hon-Yen Wu 2013 Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors Both No No
Lin 2014 Ferric sulphate versus mineral trioxide aggregate Both No No
Castellucci 2014 Unfractionated heparin and vitamin K antagonist versus low molecular weight heparin and 
vitamin K antagonist
Both Yes Yes
Myers 2014 Celecoxib versus tramadol Both No No
Alfirevic 2014 Vaginal misoprostol versus vaginal prostaglandin E2 Both No No
Greco 2015 Dobutamine versus levosimendan Both Yes No
Greco 2015 Dobutamine versus milrinone Both No No
Walsem 2015 Diclofenac high dose versus celecoxib Both Yes No
Singh 2015 5-aminosalicylic acid versus anti-tumour necrosis factor Both Yes No
Singh 2015 Anti-tumour necrosis factor versus placebo Both Yes No
Linde 2015 Selective serotonin reuptake inhibitors versus tricyclic and tetracyclic antidepressants Both No No
Sun 2015 Metformin versus sitagliptin Both Yes No
Leucht 2013 Haloperidol versus olanzapine Both Yes No
Ke-Qing Shi 2013 Endoscopic injection sclerotherapy versus endoscopic banding ligation Both Yes No
Stagg 2014 Isoniazid (six months) versus rifampicin and isoniazid (three-four months) Both No No
Tadrous 2014 Alendronate versus risedronate Both No No
Dong 2013 Inhaled corticosteroids versus long acting β2 agonists—inhaled corticosteroids Both No No
Stevens 2015 Standard care or placebo versus diet and exercise Both Yes Yes
Lin 2012 Chemical occlusion versus physical occlusion Both No No
Fretheim 2012 Angiotensin converting enzyme inhibitors versus calcium channel blockers Both No No
Fretheim 2012 Angiotensin receptor blockers versus calcium channel blockers Both No No
Liu 2012 Thiazolidinediones versus dipeptidyl peptidase-4 inhibitors Both No No
Lori 2012 Amiodarone intravenous versus flecainide intravenous Both No No
Ara 2012 Orlistat versus standard care Both Yes Yes
Gray 2012 Orlistat versus lifestyle Both Yes Yes
Chatterjee 2013 Metoprolol versus bisoprolol Indirect No NE
Mavranezouli 2013 Sertraline versus diazepam Indirect No NE
Akshintala 2013 Non-steroidal anti-inflammatory drugs versus nafamostat Indirect No NE
Bodalia 2013 Pregabalin versus gabapentin Indirect No NE
Kew 2014 Glycopyrronium bromide versus budesonide Indirect No NE
Windecker 2014 Everolimus eluting stent versus coronary artery bypass grafting Indirect No NE
Kriston 2014 Fluoxetine versus escitalopram Indirect No NE
Dong 2015 Exercise and non-steroidal anti-inflammatory drugs versus exercise Indirect Yes NE
Rotta 2013 Terbinafine versus flutrimazole Indirect No NE
Murad 2012 Alendronate versus denosumab Indirect No NE
Ramsberg 2012 Amitriptyline versus fluoxetine Indirect No NE
Haas 2012 Nifedipine versus placebo Indirect Yes NE
Shamiliyan 2012 Candesortom versus topiramate Indirect Yes NE
Shi 2013 Endoscopic banding ligation versus endoscopic banding ligation and endoscopic injection 
sclerotherapy
Direct No No
Dogliotti 2013 Vitamin K antagonists versus rivaroxab Direct No No
Pechlivanoglou 2013 Posaconazole versus fluconazole Direct Yes Yes
Yang 2014 Edaravone versus placebo Direct Yes Yes
Zoccai 2014 Iopromide versus iodixanol Direct No No
Samarasekera 2013 Potent corticosteroid versus placebo Direct Yes Yes
Terasawa 2012 Fludarabine-rituximab-based chemoimmunotherapies versus fludarabine based combina-
tion regimens
Direct No No
NE=not estimable.
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discussion
This study found that among 49 treatment comparisons 
deemed important for guideline development and 
clinical practice, prospectively planned, living network 
meta-analysis was 20% more likely to produce strong 
evidence against the null hypothesis than living 
pairwise meta-analysis that was based on direct 
evidence only. Strong evidence became available four 
years earlier with network meta-analysis compared with 
pairwise meta-analysis. Of note, studies comparing the 
two treatments of interest continued to be published 
even after strong evidence had become available. This 
is an important finding with implications for clinical 
research, especially in the context of the debate about 
research waste.20 36-38 As per the inclusion criteria, the 
findings of this study apply to treatment comparisons 
for which a considerable amount of data have 
accumulated over at least 10 years.
Strengths and weaknesses of this study
Several authors have argued that network meta-analyses 
and indirect treatment comparisons should be more 
frequently used to inform healthcare and regulatory 
decisions.39-43 One of these studies analysed a network 
of interventions for primary open angle glaucoma 
and found that network meta-analysis showed the 
advantage of prostaglandins 10 years before they were 
recommended in clinical guidelines.39 In our study 
we empirically assessed the frequency of and time to 
strong evidence in comparative effectiveness research 
using network or traditional pairwise meta-analysis. 
Although the sample size was small (49 comparisons) 
we believe it is likely to represent situations where 
guideline developers and clinical decision makers 
might consider network meta-analysis.
We mimicked the situation of a prospectively 
planned living network or pairwise meta-analysis 
and asked clinical experts to choose the treatment 
comparisons that were of topical interest during 
the period the evidence accumulated. We restricted 
the data to networks that did not show evidence 
of statistical inconsistency for the comparisons 
of interest, and excluded only five networks with 
evidence of inconsistency; this is in line with previous 
studies that have shown that direct and indirect 
comparisons in a network disagree in about 10% 
of comparisons.44 45 However, we cannot rule out 
inconsistency in some of the comparisons evaluated; 
statistical tests for inconsistency have low power to 
detect inconsistency.46 47 One in eight networks was 
previously found to show evidence of inconsistency 
using the design-by-treatment test; this means that our 
methods would not be applicable in, on average, one 
in eight networks.44
Our study has some limitations. We reanalysed 
published networks that did not show statistical 
inconsistency, but we did not examine the overall 
quality of the evidence they provided. We acknowledge 
that strong evidence against the null hypothesis does not 
necessarily translate into strong recommendations.48 
Guideline panels typically consider the quality of 
evidence in the results from meta-analysis before 
making recommendations, often using the GRADE 
system.49 Evaluation of the confidence in the results 
from network meta-analysis is a matter of ongoing 
research,50-52 and none of the included networks in 
our database attempted such an evaluation. We did 
not consider other components such as the risk of 
publication bias, the limitations of the RCTs included in 
the networks, or the comprehensiveness of the literature 
search and accuracy of the data extraction. Selective 
publication of studies of the comparison of interest 
or of studies of comparisons that contributed indirect 
evidence or a high risk of bias in the conduct and 
analysis of studies, could have affected our conclusions. 
Finally, we acknowledge that evidence against the null 
hypothesis based on P values might be of greater interest 
to regulatory agencies than to guideline developers. 
Interpretation of the 95% confidence interval of the 
treatment effect in the context of worthwhile effects 
are more useful for decision making.53 54 Although 
recently published networks, such as those included 
here, conform with high methodological standards,55 
the strength of recommendations from pairwise and 
network meta-analyses should be compared in future 
studies.
Relation to other studies and implications
Protocols for living pairwise and network meta-
analyses have been published recently,56-58 and 
Table 3 | Number of comparisons with strong evidence against the null hypothesis from 
pairwise and network meta-analysis. Values are numbers (percentages) unless stated 
otherwise
Pairwise meta-analysis
Network meta-analysis
Total P value*Yes No
Yes 7 (14) 0 (0) 7 (14) 0.002
No 10 (20) 32 (65) 42 (86)
Total 17 (35) 32 (65) 49 (100)
*McNemar’s exact test.
The anticipated relative treatment effect was set equal to the final estimate from network meta-analysis. 
Heterogeneity variance was imputed as the median value of its empirical distribution.27 28
Years since inclusion of comparison interest in network
Pr
op
or
tio
n 
of
 co
m
pa
ris
on
s
wi
th
ou
t s
tro
ng
 e
vi
de
nc
e
0 10 20 30
0
0.2
0.4
0.6
0.8
1.0
Pairwise meta-analysis
Network meta-analysis
Incidence rate: 0.026,
median survival 19 years
Incidence rate: 0.009,
median survival 23 years
Fig 2 | Kaplan-Meier survival curves for non-strong 
evidence against null hypothesis, comparing sequential 
pairwise and network meta-analysis of 49 comparisons. 
Events occur when monitoring boundaries are crossed 
for comparison of interest. Time is measured as years 
from time point when both interventions are included in 
network
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health technology assessment agencies, the World 
Health Organization, and drug licensing bodies 
have recognised the value of synthesising direct 
and indirect evidence in network meta-analysis.19  21 
41  59 The concept of living meta-analysis is in line 
with the goal to continuously update guidelines and 
to promptly translate results to recommendations, 
evidence summaries, and decision aids.60 61 Our 
findings suggest that the gain in including both direct 
and indirect evidence when synthesising data from 
clinical research is substantial as it can considerably 
reduce the time to strong evidence against the null 
hypothesis.
We found that one in four of the comparisons 
was not directly compared in RCTs. This might be 
partly explained by the tendency of pharmaceutical 
companies to test drugs against placebo or suboptimal 
interventions, rather than the reference treatment 
given in routine practice.62 Taking into account direct 
and indirect evidence, the median time to obtain 
strong evidence against the null hypothesis about 
comparisons of interest was 19 years. Consequently, 
even in cases where direct evidence exists, it is 
important to strengthen the evidence base using 
network meta-analysis.
Unanswered questions and future work
Our results indicate that living network meta-analysis 
has the potential to reduce research waste and optimise 
the use of available evidence.17 Further research is 
needed to better understand the role of living meta-
analysis in the prevention of research waste. Previous 
studies showed that the impact of available data on the 
design of subsequent research is generally low.63 66 We 
found that in about half of the comparisons for which 
strong evidence emerged from living network meta-
analysis, further studies were conducted after the 
evidence was already available. We did not assess these 
studies to determine whether they were scientifically 
and ethically justified but are planning such work in 
the future.
Methodologists are debating the use of sequential 
methods for cumulative meta-analysis. In particular, 
there is concern about encouraging inference based on 
statistical rather than clinical significance (see box). 
The statistical routines are not widely available, and 
Box 1: Do researchers agree on the use of sequential methods in meta-analysis?
Consensus on the appropriateness of applying sequential methods in meta-analysis is lacking. The arguments against their use are mainly 
twofold: the suspicion that sequential methods encourage inferences on the basis of statistical significance and concerns about meta-analysis 
influencing decisions on the design of future trials.1 2 In our view, interpretation of meta-analysis results should emphasise the uncertainty 
surrounding effect estimates, irrespective of the use of sequential analysis. Uncertainty over stopping decisions can be expressed and inspected 
through repeated confidence intervals, which can be drawn in a forest plot along with confidence intervals (see appendix M)3 4
Concerns about the influence of meta-analyses on future primary research has also contributed to the scepticism. In particular, detractors of the 
notion of sequential meta-analysis have questioned the analogy between stopping trials and stopping meta-analyses and wondered whether a 
decision of “no further updating warranted” would be reasonable.2 Editors of Cochrane review groups have indeed “closed a review,” judging that 
it is not likely that further evidence would challenge current conclusions, and therefore new trials are deemed unnecessary, costly, and unethical.5 
6 Authors of systematic reviews are not in a position to decide whether further studies are done and to define their design. What they should do, 
however, is to provide recommendations for research, to identify potential gaps in the existing evidence base, and to discuss the implications of 
their reviews for future research.2 3 7-11
The application of sequential methods in meta-analysis is also controversial; this controversy is mainly driven by the nature of their use and 
interpretation in practice. Sequential methods are often used to correct for multiple testing when presenting and interpreting evidence from a 
systematic review. In our view, no multiplicity is induced in the conventional process of performing meta-analysis as a retrospective activity: 
researchers simply synthesise what is already known and are not in a position to decide on carrying out further studies.2 Retrospective application 
of sequential methods in meta-analysis in line with recommendations for cumulative meta-analysis7 should be done for illustrative purposes only.
However, in a prospective meta-analysis setting where studies are planned and analysed sequentially to answer a research question, control of 
type I error through sequential methods is desirable.12 Researchers undertaking such living systematic reviews have to decide a priori and 
describe in a protocol if and when the review is going to be terminated. If this decision is linked to whether treatment effects provide strong 
evidence against the null hypothesis or not, adjustment for multiple testing becomes important. Empirical results presented in this paper should 
be seen as an illustration of hypothetical living networks of prospectively planned studies rather than as an attempt to define the need of future 
research in the examined healthcare areas. Depending on whether researchers plan to simply describe implications for research, provide concrete 
recommendations for filling evidence gaps, or actively direct future research, use of sequential methods might be less or more imperative. In our 
view, the optimal use of living systematic reviews will be to highlight gaps and certainties in a body of evidence and provide research funders and 
regulators with the best evidence to decide whether new primary research is warranted and, if so, for which treatment comparisons.
Undertaking living systematic reviews within a bayesian framework is a possible alternative.3 13 The estimated treatment effects after each update 
form a prior for future updates. Then, approaches to monitor the accumulated evidence can be informal (eg, inspecting the estimated treatment 
effects and their precision without formally specifying a stopping criterion) or formal (eg, by defining a loss function or a boundary as a basis for 
monitoring).14 15
1.  Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 1993;22:161-72.
2.  Higgins JPT. Comment on “Trial sequential analysis: methods and software for cumulative meta-analyses” by Wetterslev and colleagues. 
Cochrane Methods. Cochrane DB Syst Rev 2012;(Suppl 1):1-56. www.cochranelibrary.com/dotAsset/3d4dc937-0b49-4634-a766-ef13df169f9f.pdf.
3.  Higgins JPT, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Stat Med 2011;309:903-21.
4.  Jennison C, Turnbull BW. Repeated confidence intervals for group sequential clinical trials. Control Clin Trials 1984;51:33-45.
5.  Lacasse Y, Cates CJ, McCarthy B, Welsh EJ. This Cochrane Review is closed: deciding what constitutes enough research and where next for 
pulmonary rehabilitation in COPD. http://doi.wiley.com/10.1002/14651858.ED000107
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guidance and tutorials are lacking. The development 
of software tools and a template protocol for living 
systematic reviews are urgently needed. Further 
development of the methodology, such as the most 
appropriate approach to dealing with heterogeneity in 
a sequential meta-analysis, is another priority.11 22
In the present work, we focused on detecting 
differences between interventions. It is also possible to 
construct futility stopping boundaries,18 and empirical 
evidence about the relative advantage of network meta-
analysis in this context is required. Such an extension 
might be particularly useful considering that we could 
not detect statistically significant differences in two out 
of three comparisons. We selected only one treatment 
comparison for each network, although decision 
making may involve several treatments included in 
the network. Future studies should investigate the 
superiority or non-inferiority of several competing 
treatments.
Conclusions
Continuously updated systematic reviews to inform 
guidelines and clinical decision making may provide 
strong evidence against the null hypothesis more 
frequently and earlier if both direct and indirect 
accumulating evidence is considered within the 
framework of a living network meta-analysis.
AUTHOR AFFILIATIONS
1Institute of Social and Preventive Medicine (ISPM), University of 
Bern, Bern, Switzerland
2Department of Primary Education, University of Ioannina, Ioannina, 
Greece
3Centre de Recherche Épidémiologie et Statistique Sorbonne Paris 
Cité, Inserm/Université Paris Descartes, Paris, France
4Departments of Health Promotion and Human Behavior and 
of Clinical Epidemiology, Kyoto University Graduate School of 
Medicine/School of Public Health, Kyoto, Japan
5Department of Psychiatry, University of Oxford, Warneford Hospital, 
Oxford, UK
6Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
7Knowledge Translation Program, Li Ka Shing Knowledge Institute, 
St Michael’s Hospital, Toronto, Ontario, Canada
8Epidemiology Division, Dalla Lana School of Public Health, 
University of Toronto, Toronto, Ontario, Canada
9Department of Medicine, Faculty of Medicine, University of Toronto, 
Toronto, Ontario, Canada
10Department of Cardiology, Bern University Hospital, Bern, 
Switzerland
We thank the following clinical experts who identified clinically 
relevant comparisons of highest interest and provided a relevant 
reference to guidelines (numbers in brackets refer to the relevant 
references to the included network meta-analyses, which can be 
found in appendix C): Graziella Filippini for reviewing a network 
on multiple sclerosis,[4] Maria Kyrgiou for reviewing a network on 
labour induction,[10] Niklaus Meier for reviewing a network on 
migraine,[44] Nikolaos Pandis for reviewing three networks on 
dentistry and periodontology,[1, 7, 34] and Stephan Reichenbach for 
reviewing three networks on rheumatology.[9, 12, 41] We also thank 
Akhil Parashar, Karan Sud, Apostolos Tsapas, Sara Mazzucco, and 
Klaus Linde for discussions on the process to select the comparison 
of highest interest in a previous version of this project; and Maria 
Petropoulou, Areti-Angeliki Veroniki, Patricia Rios, Afshin Vafaei, 
Wasifa Zarin, Myrsini Giannatsi, Shannon Sullivan, and Anna Chaimani 
for their contribution to building the database of network meta-
analyses that we used for this study.
Contributors: GS and ME conceived and designed the study. 
TAF, AC, ACT, SES, and GCMS assisted in the design of the study, 
indicated the relevant comparisons of highest interest for their 
specialties of expertise, and provided a relevant reference to 
guidelines. AN compiled the database of eligible networks and 
performed the analysis. AN drafted the manuscript. TAF and AC 
assessed network meta-analyses pertaining to mental health, ACT 
and SES assessed networks in the specialties of endocrinology, 
dermatology, gastroenterology, obstetrics, oncology, anaesthesiology, 
and hepatology, and GCMS assessed network meta-analyses 
from the specialty of cardiology. For networks examining other 
conditions, external medical doctors or experienced researchers were 
approached. All authors critically revised the manuscript, interpreted 
the results, and performed a critical review of the manuscript for 
intellectual content. GS and ME produced the final version of the 
submitted article, and all coauthors approved it. AN and GS had full 
access to all data in the study and take responsibility for the integrity 
of the data and the accuracy of the analysis. GS and ME are the 
guarantors.
Funding: ACT is funded by a tier 2 Canada research chair in 
knowledge synthesis. SES is funded by a tier 1 Canada research chair 
in knowledge translation. GS received funding from a Horizon 2020 
Marie-Curie individual fellowship (grant No 703254). AC is supported 
by the National Institute for Health Research Oxford cognitive health 
clinical research facility. The sponsors had no influence on the design, 
analysis, and reporting of this study, neither on the preparation of the 
manuscript.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: 
Box 1: (Continued)
 6.  Sutton AJ, Donegan S, Takwoingi Y, Garner P, Gamble C, Donald A. An encouraging assessment of methods to inform priorities for updating 
systematic reviews. J Clin Epidemiol 2009;623:241-51.
 7.  Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley; 2011:434.
 8.  Chapman E, Reveiz L, Chambliss A, Sangalang S, Bonfill X. Cochrane systematic reviews are useful to map research gaps for decreasing 
maternal mortality. J Clin Epidemiol 2013;661:105-12.
 9.  Higgins JP, Green S, Scholten RJ. Maintaining Reviews: Updates, Amendments and Feedback. In: Higgins JP, Green S, eds. Cochrane Handbook for 
Systematic Reviews of Interventions. Chichester, UK: Wiley; 2008:31-49 [cited 2014 Jul 16]. http://doi.wiley.com/10.1002/9780470712184.ch3
10.  Habre C, Tramèr MR, Pöpping DM, Elia N. Ability of a meta-analysis to prevent redundant research: systematic review of studies on pain from 
propofol injection. BMJ 2014;348:g5219.
11.  Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JPT, Mavergames C, et al. Living systematic reviews: an emerging opportunity to narrow the 
evidence-practice gap. PLoS Med 2014;18:112:e1001603.
12.  Whitehead A. A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials. Stat Med 1997;1624:2901-13.
13.  Spence GT, Steinsaltz D, Fanshawe TR. A Bayesian approach to sequential meta-analysis. Stat Med 2016: 1 Aug.
14.  Spiegelhalter DJ, Abrams KR, Myles JP. Randomised controlled trials. In: Bayesian approaches to clinical trials and health-care evaluation. 
Wiley; 2003:181-249.
15.  Freedman LS, Spiegelhalter DJ. Comparison of Bayesian with group sequential methods for monitoring clinical trials. Control Clin Trials 
1989;104:357-67.
RESEARCH
the bmj | BMJ 2018;360:k585 | doi: 10.1136/bmj.k585 9
no support from any organisation for the submitted work; TAF 
has received lecture fees from Eli Lilly, Janssen, Meiji, Mitsubishi-
Tanabe, MSD, and Pfizer and consultancy fees from Takeda Science 
Foundation. He has received research support from Mochida and 
Mitsubishi-Tanabe; no other relationships or activities that could 
appear to have influenced the submitted work.
Ethical approval: Not required.
Data sharing: List of included studies and details about the data are 
reported in the appendix. Study level data and R codes are available 
in a GitHub repository. Instructions to access them can be found in 
appendix N.
Transparency: The lead author (GS) affirms that the manuscript is 
an honest, accurate, and transparent account of the study being 
reported; that no important aspects of the study have been omitted; 
and that any discrepancies from the study as planned (and, if relevant, 
registered) have been explained.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different 
terms, provided the original work is properly cited and the use is non-
commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
1 Egger M, Smith GD. Meta-Analysis. Potentials and promise. BMJ 
1997;315:1371-4. 10.1136/bmj.315.7119.1371 
2 Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic 
reviews. Ann Intern Med 1997;127:820-6. 10.7326/0003-4819-
127-9-199711010-00008 
3 Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. 
A comparison of results of meta-analyses of randomized control 
trials and recommendations of clinical experts. Treatments 
for myocardial infarction. JAMA 1992;268:240-8. 10.1001/
jama.1992.03490020088036 
4 Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, 
Chalmers TC. Cumulative meta-analysis of therapeutic trials for 
myocardial infarction. N Engl J Med 1992;327:248-54. 10.1056/
NEJM199207233270406 
5 Moher D, Tsertsvadze A, Tricco A. When and how to update 
systematic reviews. In: The Cochrane Collaboration, editor. 
Cochrane Database of Systematic Reviews. Chichester, UK: John 
Wiley & Sons, Ltd; 2008 [cited 2014 Mar 21]. http://doi.wiley.
com/10.1002/14651858.MR000023.pub3
6 Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How 
quickly do systematic reviews go out of date? A survival analysis. 
Ann Intern Med 2007;147:224-33. 10.7326/0003-4819-147-4-
200708210-00179 
7 French SD, McDonald S, McKenzie JE, Green SE. Investing in updating: 
how do conclusions change when Cochrane systematic reviews are 
updated?BMC Med Res Methodol 2005;5:33. 10.1186/1471-2288-
5-33 
8 Ahmadzai N, Newberry SJ, Maglione MA, et al. A surveillance 
system to assess the need for updating systematic reviews. Syst 
Rev 2013;2:104. 10.1186/2046-4053-2-104 
9 Garner P, Hopewell S, Chandler J, et al, Panel for updating guidance 
for systematic reviews (PUGs). When and how to update systematic 
reviews: consensus and checklist. BMJ 2016;354:i3507. 10.1136/
bmj.i3507 
10 Takwoingi Y, Hopewell S, Tovey D, Sutton AJ. A multicomponent 
decision tool for prioritising the updating of systematic reviews. 
BMJ 2013;347:f7191. 10.1136/bmj.f7191 
11 Elliott JH, Turner T, Clavisi O, et al. Living systematic reviews: an 
emerging opportunity to narrow the evidence-practice gap. PLoS 
Med 2014;11:e1001603. 10.1371/journal.pmed.1001603 
12 Petropoulou M, Nikolakopoulou A, Veroniki A-A, et al. Bibliographic 
study showed improving statistical methodology of network 
meta-analyses published between 1999 and 2015. J Clin 
Epidemiol 2016;82:20-28.
13 Bafeta A, Trinquart L, Seror R, Ravaud P. Analysis of the systematic 
reviews process in reports of network meta-analyses: methodological 
systematic review. BMJ 2013;347:f3675.
14 Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of 
multiple treatments: combining direct and indirect evidence. 
BMJ 2005;331:897-900.
15 Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical 
challenges in network meta-analysis. Ann Intern Med 2013;159: 
130-7. 10.7326/0003-4819-159-2-201307160-00008 
16 Li T, Puhan MA, Vedula SS, Singh S, Dickersin K, Ad Hoc Network 
Meta-analysis Methods Meeting Working Group. Network meta-
analysis-highly attractive but more methodological research is 
needed. BMC Med 2011;9:79. 10.1186/1741-7015-9-79 
17 Vandvik PO, Brignardello-Petersen R, Guyatt GH. Living cumulative 
network meta-analysis to reduce waste in research: A paradigmatic 
shift for systematic reviews? BMC Med 2016 Dec [cited 2017 Apr 
5];14(1). http://bmcmedicine.biomedcentral.com/articles/10.1186/
s12916-016-0596-4
18 Nikolakopoulou A, Mavridis D, Egger M, Salanti G. Continuously 
updated network meta-analysis and statistical monitoring for timely 
decision-making. Stat Methods Med Res 2016;962280216659896.
19 Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, Bansback N. Use 
of network meta-analysis in clinical guidelines. Bull World Health 
Organ 2016;94:782-4. 10.2471/BLT.16.174326 
20 Créquit P, Trinquart L, Yavchitz A, Ravaud P. Wasted research 
when systematic reviews fail to provide a complete and up-
to-date evidence synthesis: the example of lung cancer. BMC 
Med 2016;14:8. 10.1186/s12916-016-0555-0 
21 Naci H, O’Connor AB. Assessing comparative effectiveness of new 
drugs before approval using prospective network meta-analyses. 
J Clin Epidemiol 2013;66:812-6. 10.1016/j.jclinepi.2013.04.002 
22 Higgins JPT, Whitehead A, Simmonds M. Sequential methods for 
random-effects meta-analysis. Stat Med 2011;30:903-21. 10.1002/
sim.4088 
23 Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in 
mixed treatment comparison meta-analysis. Stat Med 2010;29: 
932-44. 10.1002/sim.3767 
24 Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis 
may establish when firm evidence is reached in cumulative 
meta-analysis. J Clin Epidemiol 2008;61:64-75. 10.1016/j.
jclinepi.2007.03.013 
25 Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive 
findings in Cochrane meta-analyses with and without 
application of trial sequential analysis: an empirical review. BMJ 
Open 2016;6:e011890. 10.1136/bmjopen-2016-011890 
26 Simmonds M, Salanti G, McKenzie J, Elliott J, Living Systematic 
Review Network. Living systematic reviews: 3. Statistical methods 
for updating meta-analyses. J Clin Epidemiol 2017;91:38-46. 
10.1016/j.jclinepi.2017.08.008 
27 Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting 
the extent of heterogeneity in meta-analysis, using empirical 
data from the Cochrane Database of Systematic Reviews. Int J 
Epidemiol 2012;41:818-27. 10.1093/ije/dys041 
28 Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were 
developed for the extent of heterogeneity in meta-analyses of 
continuous outcome data. J Clin Epidemiol 2015;68:52-60. 
10.1016/j.jclinepi.2014.08.012 
29 Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and 
tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-
treatments meta-analysis. Lancet 2013;382:951-62. 10.1016/
S0140-6736(13)60733-3 
30 Beasley CMJr, Tollefson G, Tran P, Satterlee W, Sanger T, 
Hamilton S. Olanzapine versus placebo and haloperidol: 
acute phase results of the North American double-blind 
olanzapine trial. Neuropsychopharmacology 1996;14:111-23. 
10.1016/0893-133X(95)00069-P 
31 Vaupel JW, Manton KG, Stallard E. The impact of heterogeneity 
in individual frailty on the dynamics of mortality. 
Demography 1979;16:439-54. 10.2307/2061224 
32 Dong W, Goost H, Lin X-B, et al. Treatments for shoulder 
impingement syndrome: a PRISMA systematic review and network 
meta-analysis. Medicine (Baltimore) 2015;94:e510. 10.1097/
MD.0000000000000510 
33 Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic 
therapy for preterm delivery: systematic review and network meta-
analysis. BMJ 2012;345:e6226. 10.1136/bmj.e6226 
34 Shamliyan TA, Kane RL, Taylor FR. Migraine in Adults: Preventive 
Pharmacologic Treatments [Internet]. Rockville (MD): Agency for 
Healthcare Research and Quality (US); 2013 [cited 2016 Dec 22]. 
(AHRQ Comparative Effectiveness Reviews). Available from: http://
www.ncbi.nlm.nih.gov/books/NBK138287/
35 Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and safety of therapies 
for acute ischemic stroke in China: a network meta-analysis of 
13289 patients from 145 randomized controlled trials. PLoS 
One 2014;9:e88440. 10.1371/journal.pone.0088440 
36 Moher D, Glasziou P, Chalmers I, et al. Increasing value and 
reducing waste in biomedical research: who’s listening? 
Lancet 2016;387:1573-86. 10.1016/S0140-6736(15)00307-4 
37 Storz-Pfennig P. Potentially unnecessary and wasteful clinical trial 
research detected in cumulative meta-epidemiological and trial 
sequential analysis. J Clin Epidemiol 2017;82:61-70. 10.1016/j.
jclinepi.2016.11.003 
38 Li T, Vedula SS, Scherer R, Dickersin K. What comparative 
effectiveness research is needed? A framework for using guidelines 
and systematic reviews to identify evidence gaps and research 
priorities. Ann Intern Med 2012;156:367-77. 10.7326/0003-4819-
156-5-201203060-00009 
39 Rouse B, Cipriani A, Shi Q, Coleman AL, Dickersin K, Li T. Network 
Meta-analysis for Clinical Practice Guidelines: A Case Study on First-
Line Medical Therapies for Primary Open-Angle Glaucoma. Ann Intern 
Med 2016;164:674-82. 10.7326/M15-2367 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
40 Leucht S, Chaimani A, Cipriani AS, Davis JM, 
Furukawa TA, Salanti G. Network meta-analyses should be 
the highest level of evidence in treatment guidelines. Eur Arch 
Psychiatry Clin Neurosci 2016;266:477-80. 10.1007/s00406-016-
0715-4 
41 Eichler H-G, Thomson A, Eichler I, Schneeweiss S. Assessing the 
relative efficacy of new drugs: an emerging opportunity. Nat Rev Drug 
Discov 2015;14:443-4. 10.1038/nrd4664 
42 Higgins JPT, Welton NJ. Network meta-analysis: a norm for 
comparative effectiveness?Lancet 2015;386:628-30. 10.1016/
S0140-6736(15)61478-7 
43 Naci H, van Valkenhoef G, Higgins JPT, Fleurence R, Ades AE. 
Evidence-based prescribing: combining network meta-analysis 
with multicriteria decision analysis to choose among multiple 
drugs. Circ Cardiovasc Qual Outcomes 2014;7:787-92. 10.1161/
CIRCOUTCOMES.114.000825 
44 Veroniki AA, Vasiliadis HS, Higgins JPT, Salanti G. Evaluation 
of inconsistency in networks of interventions. Int J 
Epidemiol 2013;42:332-45. 10.1093/ije/dys222 
45 Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, Eastwood AJ, 
et al, Inconsistency between direct and indirect comparisons 
of competing interventions: meta-epidemiological study. 
BMJ 2011;343:d4909.
46 Song F, Clark A, Bachmann MO, Maas J. Simulation evaluation of 
statistical properties of methods for indirect and mixed treatment 
comparisons. BMC Med Res Methodol 2012 Dec [cited 2017 
Apr 6];12(1). http://bmcmedresmethodol.biomedcentral.com/
articles/10.1186/1471-2288-12-138
47 Veroniki AA, Mavridis D, Higgins JP, Salanti G. Characteristics of a loop 
of evidence that affect detection and estimation of inconsistency: 
a simulation study. BMC Med Res Methodol 2014 Dec [cited 2017 
Apr 6];14(1). http://bmcmedresmethodol.biomedcentral.com/
articles/10.1186/1471-2288-14-106
48 Guyatt GH, Oxman AD, Vist GE, et al, GRADE Working Group. 
GRADE: an emerging consensus on rating quality of evidence and 
strength of recommendations. BMJ 2008;336:924-6. 10.1136/
bmj.39489.470347.AD 
49 Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. 
Introduction-GRADE evidence profiles and summary of 
findings tables. J Clin Epidemiol 2011;64:383-94. 10.1016/j.
jclinepi.2010.04.026 
50 Puhan MA, Schünemann HJ, Murad MH, et al, GRADE Working Group. 
A GRADE Working Group approach for rating the quality of treatment 
effect estimates from network meta-analysis. BMJ 2014;349:g5630. 
10.1136/bmj.g5630 
51 Salanti G, Del Giovane C, Chaimani A, Caldwell DM, 
Higgins JPT. Evaluating the quality of evidence from a network 
meta-analysis. PLoS One 2014;9:e99682. 10.1371/journal.
pone.0099682 
52 Brignardello-Petersen R, Bonner A, Alexander PE, et al, 
GRADE Working Group. Advances in the GRADE approach 
to rate the certainty in estimates from a network meta-
analysis. J Clin Epidemiol 2018;93:36-44. 10.1016/j.
jclinepi.2017.10.005
53 Schünemann HJ. Interpreting GRADE’s levels of certainty or 
quality of the evidence: GRADE for statisticians, considering 
review information size or less emphasis on imprecision? J Clin 
Epidemiol 2016;75(Supplement C):6-15. 10.1016/j.jclinepi. 
2016.03.018 
54 Pogue JM, Yusuf S. Cumulating evidence from randomized trials: 
utilizing sequential monitoring boundaries for cumulative meta-
analysis. Control Clin Trials 1997;18:580-93, discussion 661-6. 
10.1016/S0197-2456(97)00051-2 
55 Zarin W, Veroniki AA, Nincic V, et al. Characteristics and knowledge 
synthesis approach for 456 network meta-analyses: a scoping 
review. BMC Med 2017;15:3. 10.1186/s12916-016-0764-6 
56 Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R. A 
Living Systematic Review of Nebulized Hypertonic Saline for Acute 
Bronchiolitis in Infants. JAMA Pediatr 2015;169:788-9. 10.1001/
jamapediatrics.2015.0681 
57 Rahal AK, Badgett RG, Hoffman RM. Screening Coverage Needed to 
Reduce Mortality from Prostate Cancer: A Living Systematic Review. 
PLoS One 2016;11:e0153417. 10.1371/journal.pone.0153417 
58 Créquit P, Trinquart L, Ravaud P. Live cumulative network meta-
analysis: protocol for second-line treatments in advanced non-small-
cell lung cancer with wild-type or unknown status for epidermal 
growth factor receptor. BMJ Open 2016;6:e011841. 10.1136/
bmjopen-2016-011841 
59 Brooks-Renney C, Costello S, Kusel J, Timm B. The use of mixed 
treatment comparisons in NICE technology appraisals. 2011;
60 EUnetHTA. Methodological guideline for REA of pharmaceuticals: 
Direct and indirect comparison. [cited 2017 Apr 24]. www.eunethta.
eu/outputs/methodological-guideline-rea-pharmaceuticals-direct-
and-indirect-comparison
61 Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, 
Vandvik PO. Introduction to BMJ Rapid Recommendations. 
BMJ 2016;354:i5191. 10.1136/bmj.i5191 
62 Mann H, Djulbegovic B. Comparator bias: why comparisons must 
address genuine uncertainties. J R Soc Med 2013;106:30-3. 
10.1177/0141076812474779 
63 Clark T, Berger U, Mansmann U. Sample size determinations 
in original research protocols for randomised clinical trials 
submitted to UK research ethics committees: review[review]. 
BMJ 2013;346:f1135. 10.1136/bmj.f1135 
64 Habre C, Tramèr MR, Pöpping DM, Elia N. Ability of a meta-analysis 
to prevent redundant research: systematic review of studies on pain 
from propofol injection. BMJ 2014;348:g5219. 10.1136/bmj.g5219 
65 Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use 
of systematic reviews in the planning, design and conduct of 
randomised trials: a retrospective cohort of NIHR HTA funded trials. 
BMC Med Res Methodol 2013;13:50. 10.1186/1471-2288-13-50 
66 Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment 
suggests that existing evidence could be used more fully in designing 
randomized controlled trials. J Clin Epidemiol 2010;63:983-91. 
10.1016/j.jclinepi.2010.01.022 
Supplementary information: additional material
